Spravato® is an FDA-approved nasal spray form of esketamine.
It is indicated for treatment-resistant depression and major depressive disorder with acute suicidal ideation.
Its approval is based on randomized, controlled clinical trials showing greater reductions in depressive symptoms compared with placebo.
How it works
Unlike traditional antidepressants that act gradually on serotonin pathways, esketamine works through glutamate signaling in the brain. This mechanism is thought to promote changes in neural connectivity that may support faster symptom improvement in some patients.
What treatment looks like
Spravato® is administered in clinic settings under direct medical supervision.
Treatment typically begins with twice-weekly sessions for the first four weeks, followed by less frequent maintenance dosing based on response and clinical judgment.
Each visit typically includes a monitored observation period to ensure safety prior to discharge.
Safety and oversight
All sessions will follow FDA and REMS requirements.
- Monitoring occurs before each treatment.
- During treatment.
- And throughout the post-treatment observation period.
Spravato® is often covered by insurance for eligible patients, depending on plan requirements. Care is coordinated with referring psychiatrists and clinicians to support continuity of care.
Transportation home is required following treatment.
